Recent outbreaks of SARS-Coronavirus and MERS-Coronavirus (CoV) have heightened awareness about the lack of vaccines or antiviral compounds approved for prevention or treatment of human or potential zoonotic CoVs. Anti-CoV drug development has long been challenged by the activity of a 3′ to 5′ proofreading exoribonuclease unique to CoVs. Recently, a promising nucleoside analogue with broad-spectrum activity against CoVs has been identified. This review will discuss progress made in the development of antiviral nucleoside and nucleotide analogues targeting viral RNA synthesis as effective therapeutics against CoV infections and propose promising strategies for combination therapy.

最近爆​​发的 SARS 冠状病毒和 MERS 冠状病毒 (CoV) 提高了人们对缺乏批准用于预防或治疗人类或潜在人畜共患 CoV 的疫苗或抗病毒化合物的认识。抗冠状病毒药物的开发长期以来一直受到冠状病毒特有的 3' 至 5' 校对核糖核酸酶活性的挑战。最近，一种有前途的核苷类似物被发现，具有广谱抗冠状病毒活性。这篇综述将讨论针对病毒 RNA 合成的抗病毒核苷和核苷酸类似物的开发进展，作为对抗 CoV 感染的有效疗法，并提出有前景的联合治疗策略。